Update on rifampin, rifabutin, and rifapentine drug interactions

Anne M. Baciewicz, Cary R. Chrisman, Christopher K. Finch, Timothy Self

Research output: Contribution to journalReview article

70 Citations (Scopus)

Abstract

Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCurrent Medical Research and Opinion
Volume29
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

rifapentine
Rifabutin
Rifampin
Drug Interactions
Oxycodone
Anti-Retroviral Agents
Itraconazole
Simvastatin
Risperidone
Poisons
Digoxin
P-Glycoprotein
Warfarin
Oral Contraceptives
Verapamil
Protease Inhibitors
PubMed
Cytochrome P-450 Enzyme System
Language

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Update on rifampin, rifabutin, and rifapentine drug interactions. / Baciewicz, Anne M.; Chrisman, Cary R.; Finch, Christopher K.; Self, Timothy.

In: Current Medical Research and Opinion, Vol. 29, No. 1, 01.01.2013, p. 1-12.

Research output: Contribution to journalReview article

Baciewicz, Anne M. ; Chrisman, Cary R. ; Finch, Christopher K. ; Self, Timothy. / Update on rifampin, rifabutin, and rifapentine drug interactions. In: Current Medical Research and Opinion. 2013 ; Vol. 29, No. 1. pp. 1-12.
@article{fe90da81f69a44be8a0c0170b045e6d7,
title = "Update on rifampin, rifabutin, and rifapentine drug interactions",
abstract = "Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.",
author = "Baciewicz, {Anne M.} and Chrisman, {Cary R.} and Finch, {Christopher K.} and Timothy Self",
year = "2013",
month = "1",
day = "1",
doi = "10.1185/03007995.2012.747952",
language = "English (US)",
volume = "29",
pages = "1--12",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Update on rifampin, rifabutin, and rifapentine drug interactions

AU - Baciewicz, Anne M.

AU - Chrisman, Cary R.

AU - Finch, Christopher K.

AU - Self, Timothy

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.

AB - Background: Rifampin is a potent inducer of both cytochrome P-450 oxidative enzymes and the P-glycoprotein transport system. Among numerous well documented, clinically significant interactions, examples include warfarin, oral contraceptives, itraconazole, digoxin, verapamil, simvastatin, and human immunodeficiency virus-related protease inhibitors. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. Rifapentine is also an inducer of drug metabolism. Methods: A literature search of English language journals from 2008 to March 2012 was completed using several databases, including PubMed, EMBASE, and SCOPUS. Search terms included rifampin, rifabutin, rifapentine AND drug interactions. Findings: Examples of clinically relevant interactions with rifampin demonstrated by recent reports include posaconazole, voriconazole, oxycodone, risperidone, mirodenafil, and ebastine. Conclusions: To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin, rifabutin, or rifapentine are added to or discontinued from medication regimens, clinicians need to be aware of these interactions. Recent studies have indicated that other transporter systems play a role in these drug interactions. As reports of rifampin drug interactions continue to grow, this review is a reminder to clinicians to be vigilant.

UR - http://www.scopus.com/inward/record.url?scp=84871364478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871364478&partnerID=8YFLogxK

U2 - 10.1185/03007995.2012.747952

DO - 10.1185/03007995.2012.747952

M3 - Review article

VL - 29

SP - 1

EP - 12

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 1

ER -